Measuring how common and how treatment-resistant difficult-to-treat Crohn's disease is in China.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, hospital-based study that uses the IOIBD 2023 definition to identify adults with difficult-to-treat Crohn's disease (DTT-CD) and collects demographic, clinical, treatment history, surgical history, and outcome data. Investigators will estimate the prevalence of DTT-CD among eligible Crohn's patients at the recruiting center and compare rates of treatment failure, recurrence, surgeries, and complex anal fistula between DTT-CD and non-DTT-CD groups. Key exclusions include unclear diagnoses, seriously missing baseline data, current enrollment in experimental drug trials, contraindications to biologics or small molecules, short bowel syndrome, and ostomy. Standard epidemiological analyses and group comparisons will be used to describe differences in efficacy and prognosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The diagnosis of Crohn's disease was confirmed;
* Patients aged 18-65;
* Informed consent was obtained voluntarily.

Exclusion Criteria:

* The diagnosis of CD was unclear;
* The clinical baseline data were missing seriously;
* Patients currently enrolled in clinical trials or receiving experimental drugs;
* Other contraindications to biologics or small molecule drugs (including active infection, pregnancy, etc.);
* Patients with short bowel syndrome;
* Patients with a small bowel or colostomy.

Where it's running

• Sixth Affiliated Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xiang Gao
• Email: gxiang@mail.sysu.edu.cn
• Phone: +86-020-38663423

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Microencapsulated Propionate vs Butyrate for Crohn's Disease in Remission

  This study tests whether microencapsulated sodium propionate can favorably alter the gut microbiota and inflammation in adults with Crohn’s disease, compared with sodium butyrate.

  Recruiting University of Padova · Padova · NCT07883044

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• Intestinal ultrasound-guided management for inflammatory bowel disease

  This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.

  Recruiting Mahidol University · Bangkok · NCT07775352

• Laser-based sizing of GI lesions during endoscopies

  This study tests whether the AccuMeasure laser tool gives more accurate and reliable lesion size measurements during colonoscopies for adults with colon polyps or Crohn’s disease than traditional endoscopic estimates.

  Recruiting Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec · NCT07770425

• A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis

  A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.

  Recruiting Catholic University of the Sacred Heart · Roma, RM · NCT07724990

• Claudin-2 Immunostaining to Detect Active or Inactive Inflammation in IBD Biopsies

  This study tests whether staining for Claudin-2 in intestinal biopsy samples can help identify active vs. inactive inflammation in people with ulcerative colitis or Crohn's disease.

  Recruiting IRCCS Policlinico S. Donato · San Donato Milanese, Mi · NCT07710287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.